A 68-year-old male with a 10-year history of COPD presents for a follow-up visit. The patient’s symptoms have been managed with short-acting bronchodilators, but he reports increasing dyspnea over the last six months and frequent use of rescue inhalers. His spirometry results show a FEV1 of 55% predicted, consistent with moderate COPD. He has experienced two exacerbations in the past year, one requiring hospitalization.

The patient is currently on a short-acting bronchodilator regimen but continues to experience symptom progression and exacerbations. His primary concern is reducing the frequency of exacerbations and improving daily lung function. How should his maintenance therapy be optimized?

The GOLD guidelines recommend initiating maintenance therapy with long-acting bronchodilators for patients with moderate to severe COPD. Long-acting bronchodilators, including both beta-agonists and anticholinergics, have been shown to improve lung function, reduce exacerbations, and enhance quality of life. Transitioning to a once-daily long-acting regimen could simplify the patient’s management and reduce the need for frequent rescue inhaler use. The choice between single-agent or dual bronchodilator therapy should be based on the patient’s exacerbation history and symptom burden.

Given this patient’s exacerbation history and declining lung function, how would you approach his maintenance therapy? Would you initiate monotherapy with a long-acting bronchodilator or consider dual bronchodilation for optimal control, and why?